These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 2527324)

  • 1. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors.
    Häusler A; Schenkel L; Krähenbühl C; Monnet G; Bhatnagar AS
    J Steroid Biochem; 1989 Jul; 33(1):125-31. PubMed ID: 2527324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
    Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
    Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.
    Bhatnagar AS; Häusler A; Schieweck K; Lang M; Bowman R
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1021-7. PubMed ID: 2149502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aromatase inhibitors on estrogen 2-hydroxylase in rat liver.
    Purba HS; King EJ; Richert P; Bhatnagar AS
    J Steroid Biochem Mol Biol; 1994 Feb; 48(2-3):215-9. PubMed ID: 8142297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
    Lamberts SW; Bruining HA; Marzouk H; Zuiderwijk J; Uitterlinden P; Blijd JJ; Hackeng WH; De Jong FH
    J Clin Endocrinol Metab; 1989 Oct; 69(4):896-901. PubMed ID: 2550511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency and specificity of CGS-16949A as an aromatase inhibitor.
    Santen RJ; Langecker P; Santner SJ; Sikka S; Rajfer J; Swerdloff R
    Endocr Res; 1990; 16(1):77-91. PubMed ID: 2139412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro potency and selectivity of the non-steroidal androgen aromatase inhibitor CGS 16949A compared to steroidal inhibitors in the brain.
    Wozniak A; Holman SD; Hutchison JB
    J Steroid Biochem Mol Biol; 1992 Oct; 43(4):281-7. PubMed ID: 1390279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel aromatase inhibitors.
    Bhatnagar AS; Häusler A; Schieweck K; Browne LJ; Bowman R; Steele RE
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):363-7. PubMed ID: 2147860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
    Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
    J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of aromatase with CGS 16949A in postmenopausal women.
    Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
    J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.
    Yue W; Brodie AM
    J Steroid Biochem Mol Biol; 1997; 63(4-6):317-28. PubMed ID: 9459198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the aromatase inhibitor, rogletimide (pyridoglutethimide), on guinea pig adrenal cell steroidogenesis and placental microsomal aromatase activity: comparison with aminoglutethimide and CGS 16949A.
    Newton CJ; Mehta A; Dowsett M
    J Steroid Biochem Mol Biol; 1991 Nov; 39(5A):723-7. PubMed ID: 1659868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
    Lønning PE; Dowsett M; Powles TJ
    J Steroid Biochem; 1990 Mar; 35(3-4):355-66. PubMed ID: 2139151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal.
    Häusler A; Monnet G; Borer C; Bhatnagar AS
    J Steroid Biochem; 1989; 34(1-6):567-70. PubMed ID: 2533953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male.
    Bhatnagar AS; Müller P; Schenkel L; Trunet PF; Beh I; Schieweck K
    J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):437-43. PubMed ID: 1532903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
    Dowsett M; Stein RC; Mehta A; Coombes RC
    Clin Endocrinol (Oxf); 1990 May; 32(5):623-34. PubMed ID: 2142026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of methods measuring aromatase activity in human placenta and rat ovary.
    Purba HS; Bhatnagar AS
    J Enzyme Inhib; 1990; 4(2):169-78. PubMed ID: 2151521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aromatase inhibitors: pharmacological aspects].
    de Crémoux P
    Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in development of aromatase inhibitors.
    Santen RJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1029-35. PubMed ID: 2149503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies of aromatase inhibitors in cultured human breast cancer cells.
    MacIndoe JH; Woods GR; Etre LA; Covey DF
    Cancer Res; 1982 Aug; 42(8 Suppl):3378s-3381s. PubMed ID: 7083203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.